Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Atricure Inc (ATRC) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 536,490
  • Shares Outstanding, K 33,240
  • Annual Sales, $ 129,760 K
  • Annual Income, $ -27,210 K
  • 36-Month Beta 0.57
  • Price/Sales 3.58
  • Price/Book 3.09

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.41 +0.84%
on 01/17/17
19.81 -21.55%
on 12/29/16
-3.00 (-16.18%)
since 12/16/16
3-Month
15.15 +2.57%
on 10/27/16
20.40 -23.82%
on 11/15/16
-1.29 (-7.66%)
since 10/17/16
52-Week
13.44 +15.63%
on 05/12/16
20.40 -23.82%
on 11/15/16
-2.71 (-14.85%)
since 01/15/16

Most Recent Stories

More News
AtriCure to Present at the 35th Annual JP Morgan Healthcare Conference

AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present...

AtriCure Names Sven Wehrwein to its Board of Directors

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Sven Wehrwein...

AtriCure to Present at the Piper Jaffray 28th Annual Healthcare Conference

AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present...

AtriCure (ATRC): Moving Average Crossover Alert

Are you a technical investor? If so, it may be time to consider AtriCure, Inc. (ATRC) for your portfolio

AtriCure Announces Approval for the cryoICE(TM) Platform in Japan

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received...

AtriCure Reports Third Quarter 2016 Financial Results

--U.S. sales of $30.6 million - up 24.0%

AtriCure Announces Upcoming Investor Conference Schedule

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Stifel...

AtriCure to Announce Third Quarter 2016 Financial Results

AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the third quarter...

AtriCure to Present at the Morgan Stanley Global Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan...

AtriCure Reports Second Quarter 2016 Financial Results

--U.S. sales of $30.9 million - up 19.9%

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as...

See More

Support & Resistance

2nd Resistance Point 16.55
1st Resistance Point 16.04
Last Price 15.54
1st Support Level 15.22
2nd Support Level 14.91

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.